These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 26806832)

  • 1. Changing bone patterns with progression of chronic kidney disease.
    Drüeke TB; Massy ZA
    Kidney Int; 2016 Feb; 89(2):289-302. PubMed ID: 26806832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adynamic bone disease is a predominant bone pattern in early stages of chronic kidney disease.
    Massy Z; Drueke T
    J Nephrol; 2017 Oct; 30(5):629-634. PubMed ID: 28405928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of uremic toxin-indoxyl sulfate on the skeletal system.
    Liu WC; Wu CC; Lim PS; Chien SW; Hou YC; Zheng CM; Shyu JF; Lin YF; Lu KC
    Clin Chim Acta; 2018 Sep; 484():197-206. PubMed ID: 29864403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adynamic bone disease: from bone to vessels in chronic kidney disease.
    Bover J; Ureña P; Brandenburg V; Goldsmith D; Ruiz C; DaSilva I; Bosch RJ
    Semin Nephrol; 2014 Nov; 34(6):626-40. PubMed ID: 25498381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathogenesis and treatment of renal osteodystrophy.
    Slatopolsky E; Gonzalez E; Martin K
    Blood Purif; 2003; 21(4-5):318-26. PubMed ID: 12944733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating Levels of Dickkopf-Related Protein 1 Decrease as Measured GFR Declines and Are Associated with PTH Levels.
    Forster CM; White CA; Turner ME; Norman PA; Ward EC; Hopman WM; Adams MA; Holden RM
    Am J Nephrol; 2020; 51(11):871-880. PubMed ID: 33238271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. When, how, and why a bone biopsy should be performed in patients with chronic kidney disease.
    Torres PU; Bover J; Mazzaferro S; de Vernejoul MC; Cohen-Solal M
    Semin Nephrol; 2014 Nov; 34(6):612-25. PubMed ID: 25498380
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New worldwide trends in presentation of renal osteodystrophy and its relationship to parathyroid hormone levels.
    Gal-Moscovici A; Popovtzer MM
    Clin Nephrol; 2005 Apr; 63(4):284-9. PubMed ID: 15847255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repression of osteocyte Wnt/β-catenin signaling is an early event in the progression of renal osteodystrophy.
    Sabbagh Y; Graciolli FG; O'Brien S; Tang W; dos Reis LM; Ryan S; Phillips L; Boulanger J; Song W; Bracken C; Liu S; Ledbetter S; Dechow P; Canziani ME; Carvalho AB; Jorgetti V; Moyses RM; Schiavi SC
    J Bone Miner Res; 2012 Aug; 27(8):1757-72. PubMed ID: 22492547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peritoneal dialysis per se is a risk factor for sclerostin-associated adynamic bone disease.
    de Oliveira RA; Barreto FC; Mendes M; dos Reis LM; Castro JH; Britto ZM; Marques ID; Carvalho AB; Moysés RM; Jorgetti V
    Kidney Int; 2015 May; 87(5):1039-45. PubMed ID: 25493951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uremic Toxicity and Bone in CKD.
    Yamamoto S; Fukagawa M
    J Nephrol; 2017 Oct; 30(5):623-627. PubMed ID: 28573386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sclerostin, Osteocytes, and Chronic Kidney Disease - Mineral Bone Disorder.
    Moysés RM; Schiavi SC
    Semin Dial; 2015; 28(6):578-86. PubMed ID: 26288182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Role of vitamin D in the pathogenesis of renal osteodystrophy].
    Nakanishi S; Fukagawa M
    Clin Calcium; 2004 Sep; 14(9):15-20. PubMed ID: 15577104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 22-Oxacalcitriol ameliorates high-turnover bone and marked osteitis fibrosa in rats with slowly progressive nephritis.
    Hirata M; Katsumata K; Masaki T; Koike N; Endo K; Tsunemi K; Ohkawa H; Kurokawa K; Fukagawa M
    Kidney Int; 1999 Dec; 56(6):2040-7. PubMed ID: 10594779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Renal osteodystrophy (3); its treatment in dialysis patients].
    Ghitu S; Oprisiu R; Benamar L; Said S; Tataru Albu A; Arsenescu I; el Esper N; Morinière P; Fournier A
    Nephrologie; 2000; 21(8):413-24. PubMed ID: 11213385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pathological analysis of renal osteodystrophy in 194 cases].
    Yu YF
    Zhonghua Bing Li Xue Za Zhi; 1991 Dec; 20(4):280-3. PubMed ID: 1813163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Study of renal osteodystrophy by bone biopsy. Age as an independent factor. Diagnostic value of bone remodeling markers].
    Jarava C; Armas JR; Palma A
    Nefrologia; 2000; 20(4):362-72. PubMed ID: 11039262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parathyroid function in chronic kidney disease: role of FGF23-Klotho axis.
    Koizumi M; Komaba H; Fukagawa M
    Contrib Nephrol; 2013; 180():110-23. PubMed ID: 23652554
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.